Literature DB >> 29759606

Factors Predicting Arrhythmia-Related Symptoms and Health-Related Quality of Life in Patients Referred for Radiofrequency Ablation of Atrial Fibrillation: An Observational Study (the SMURF Study).

Emmanouil Charitakis1, Neshro Barmano2, Ulla Walfridsson3, Håkan Walfridsson3.   

Abstract

OBJECTIVES: The purpose of this study was to correlate the arrhythmia-related symptoms and health-related quality of life (HRQoL) in patients with atrial fibrillation (AF) who are eligible for radiofrequency ablation (RFA) with a number of objective indicators.
BACKGROUND: Although the clinical consequences of AF have been studied extensively, the variation in the symptoms of patients with AF and HRQoL remains under-researched.
METHODS: We studied 192 patients eligible for RFA of AF referred to the University Hospital, Linköping, Sweden, between January 2012 and April 2014. The ASTA (Arrhythmia-Specific questionnaire in Tachycardia and Arrhythmia) symptom scale was used to assess arrhythmia-related symptoms in the patients. The ASTA HRQoL scale and the short-form 36 (SF-36) physical and mental components summaries (PCS and MCS) were used to express disease-specific and overall HRQoL of the patients, respectively.
RESULTS: Anxiety, low-grade inflammation, and left atrial dilatation significantly predicted arrhythmia-related symptoms (R2 = 0.313; p < 0.001). Depression was the most important predictor of arrhythmia-specific HRQoL (standardized beta: 0 .406), and the produced model explained a significant proportion of the variation in arrhythmia-specific HRQoL (R2 = 0.513; p < 0.001). The most important predictor of PCS was obesity (body mass index >30 kg/m2) (standardized beta: -0.301), whereas the most important predictor of MCS was anxiety (standardized beta: -0.437).
CONCLUSIONS: Anxiety, depression, and low-grade inflammation were the factors that predicted both arrhythmia-related symptoms and HRQoL in patients with AF. Obesity was the most significant predictor of patient general physical status. These factors need to be addressed in patients with AF to improve management of their disease. Intensive risk factor modification can be of great importance. (Reasons for Variations in Health Related Quality of Life and Symptom Burden in Patients With Atrial Fibrillation [SMURF]; NCT01553045).
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  anxiety; arrhythmia-related symptoms; atrial fibrillation; health-related quality of life; obesity

Mesh:

Substances:

Year:  2017        PMID: 29759606     DOI: 10.1016/j.jacep.2016.12.004

Source DB:  PubMed          Journal:  JACC Clin Electrophysiol        ISSN: 2405-500X


  16 in total

Review 1.  Tackling Patient-Reported Outcomes in Atrial Fibrillation and Heart Failure: Identifying Disease-Specific Symptoms?

Authors:  Benjamin A Steinberg; Jonathan P Piccini
Journal:  Cardiol Clin       Date:  2019-05       Impact factor: 2.213

2.  Predictors of improvement in arrhythmia-specific symptoms and health-related quality of life after catheter ablation of atrial fibrillation.

Authors:  Neshro Barmano; Emmanouil Charitakis; Jan-Erik Karlsson; Fredrik H Nystrom; Håkan Walfridsson; Ulla Walfridsson
Journal:  Clin Cardiol       Date:  2018-12-21       Impact factor: 2.882

Review 3.  Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management.

Authors:  Jakub Gumprecht; Magdalena Domek; Gregory Y H Lip; Alena Shantsila
Journal:  J Hum Hypertens       Date:  2019-11-05       Impact factor: 3.012

4.  Atrial fibrillation burden, episode duration and frequency in relation to quality of life in patients with implantable cardiac monitor.

Authors:  Victoria Jansson; Lennart Bergfeldt; Jonas Schwieler; Göran Kennebäck; Aigars Rubulis; Steen M Jensen; Pekka Raatikainen; Elena Sciaraffia; Carina Blomström-Lundqvist
Journal:  Int J Cardiol Heart Vasc       Date:  2021-05-11

5.  The association between alcohol consumption, cardiac biomarkers, left atrial size and re-ablation in patients with atrial fibrillation referred for catheter ablation.

Authors:  Neshro Barmano; Emmanouil Charitakis; Robert Kronstrand; Ulla Walfridsson; Jan-Erik Karlsson; Håkan Walfridsson; Fredrik H Nystrom
Journal:  PLoS One       Date:  2019-04-10       Impact factor: 3.240

6.  Echocardiographic and Biochemical Factors Predicting Arrhythmia Recurrence After Catheter Ablation of Atrial Fibrillation-An Observational Study.

Authors:  Emmanouil Charitakis; Lars O Karlsson; Joanna-Maria Papageorgiou; Ulla Walfridsson; Carl-Johan Carlhäll
Journal:  Front Physiol       Date:  2019-10-02       Impact factor: 4.566

7.  Effects of occlusal disharmony on susceptibility to atrial fibrillation in mice.

Authors:  Kenji Suita; Yuka Yagisawa; Yoshiki Ohnuki; Daisuke Umeki; Megumi Nariyama; Aiko Ito; Yoshio Hayakawa; Ichiro Matsuo; Yasumasa Mototani; Yasutake Saeki; Satoshi Okumura
Journal:  Sci Rep       Date:  2020-08-13       Impact factor: 4.379

8.  Psychological Distress and Suicidal Ideation in Patients With Atrial Fibrillation: Prevalence and Response to Management Strategy.

Authors:  Tomos E Walters; Kate Wick; Gabriel Tan; Megan Mearns; Stephen A Joseph; Joseph B Morton; Prashanthan Sanders; Christina Bryant; Peter M Kistler; Jonathan M Kalman
Journal:  J Am Heart Assoc       Date:  2018-09-18       Impact factor: 5.501

9.  Patients' Experiences of Living with Atrial Fibrillation: A Mixed Methods Study.

Authors:  Marie Stridsman; Anna Strömberg; Jeroen Hendriks; Ulla Walfridsson
Journal:  Cardiol Res Pract       Date:  2019-12-03       Impact factor: 1.866

10.  Relationship between diabetes mellitus and atrial fibrillation prevalence in the Polish population: a report from the Non-invasive Monitoring for Early Detection of Atrial Fibrillation (NOMED-AF) prospective cross-sectional observational study.

Authors:  Jakub Gumprecht; Gregory Y H Lip; Adam Sokal; Beata Średniawa; Katarzyna Mitręga; Jakub Stokwiszewski; Łukasz Wierucki; Aleksandra Rajca; Marcin Rutkowski; Tomasz Zdrojewski; Tomasz Grodzicki; Jarosław Kaźmierczak; Grzegorz Opolski; Zbigniew Kalarus
Journal:  Cardiovasc Diabetol       Date:  2021-06-24       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.